演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

当院におけるBRAF遺伝子変異を有する切除不能進行再発大腸癌の検討

演題番号 : P17-5

[筆頭演者]
演者)畑中 一映:1 
[共同演者]
吉田 苑永:1、宮本 秀一:1、木下 賢治:1、伊藤 淳:1、工藤 大樹:1、山本 義也:1、成瀬 宏仁:1

1:市立函館病院・消化器内科

 

[Background] BRAF V600E mutation is reported with the frequency of the 4.5-6.7% of colorectal cancer in Japan. BRAF V600E mutation has been reported as a bad factor. FOLFOXIRI+Bevacizumab treatment is considered as the first choice at the treatment for patients with BRAF mutant colorectal cancer in European guideline as a result of the TRIBE
study, but we cannot examine the BRAF V600E mutation in daily practice because of insurance refund. So we may not choose the best regimen for patients with BRAF mutation. [Purpose] To clear the problems at patients with BRAF mutant metastatic colorectal cancer by retrospective research. [Methods] 7 patients whose BRAF mutation was confirmed in our hospital from July 2012 to December 2017 were examined retrospectively. Genetic mutation was checked after chemotherapy treatment start at all patients. [Results] In 7 cases of BRAF mutation, 4 cases were patients with V600E mutation, and 3 cases were non-V600E mutation. Overall Survival(OS) of 4 patients with BRAF V600E mutation was 3 months(mo.), 7mo., 9mo., and 23mo. respectively. OS of 3 patients with non-V600E mutation was 27 mo., 62 mo., 76mo. Respectively. All patients were not treated by FOLFOXIRI+Bevacizumab regimen. [Summary] As a small number cases in this study, the BRAF V600E mutant colorectal cancer patients were resistant to chemotherapy treatment. It is necessary that the BRAF V600E mutation would be examined before chemotherapy start, and the best treatment woud be chosen.

キーワード

臓器別:大腸・小腸

手法別:化学療法

前へ戻る